바로가기  >

Abstract

In 2010, NRG Oncology published the initial results (3-year data) of their multicenter, single-arm, phase 2 NRG Oncology RTOG 0236 trial using sterotactic body radiation therapy (SBRT) to achieve a potent dose in patients with medically inoperable, clinically staged early lung cancer.1 Despite its rapid acceptance as a standard treatment, the implementation of SBRT into clinical practice has been incomplete.2 Patients enrolled in the NRG Oncology RTOG 0236 trial continued to be followed up per protocol for tumor control, toxic effects, and survival.3 In this report, we describe 5-year results specifically to understand how potential late events may influence the utility of SBRT for this frail population.

Author information

Timmerman RD1, Hu C2,3, Michalski JM4, Bradley JC4, Galvin J5, Johnstone DW6, Choy H1.
1
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas.
2
NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.
3
Sydney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
4
Department of Radiation Oncology, Washington University in St Louis, St Louis, Missouri.
5
Imaging and Radiation Oncology Core, Philadelphia, Pennsylvania.
6
Division of Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee.